Merck & Co. (MRK)
(Delayed Data from NYSE)
$103.98 USD
-1.90 (-1.79%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $104.13 +0.15 (0.14%) 9:26 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$103.98 USD
-1.90 (-1.79%)
Updated Oct 25, 2024 04:00 PM ET
Pre-Market: $104.13 +0.15 (0.14%) 9:26 AM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Will Merck (MRK) Beat Expectations This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and the new COVID-19 antiviral pill, molnupiravir when the company reports Q1 earnings.
The Zacks Analyst Blog Highlights Amgen, Chevron, Coca-Cola, Visa and Merck
by Zacks Equity Research
Amgen, Chevron, Coca-Cola, Visa and Merck have been included in this Analyst Blog.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.
5 Blue-Chip Stocks Likely to Gain on Earnings Results This Week
by Nalak Das
Five Dow stocks with positive Earnings ESP will report earnings results this week. These are: V, Ko, MRK, CVX and AMGN.
Is a Beat Likely for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others and the biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $86.46, marking a +0.78% move from the previous day.
AstraZeneca's (AZN) Enhertu sBLA Receives FDA Priority Tag
by Zacks Equity Research
FDA grants priority review to AstraZeneca (AZN) and Daiichi Sankyo's sBLA seeking approval of Enhertu for previously treated HER2-mutant metastatic non-small cell lung cancer (NSCLC).
Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.
Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag
by Zacks Equity Research
The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.
Nektar (NKTR) Ends Bempeg Plus Opdivo Program on Study Failures
by Zacks Equity Research
Nektar's (NKTR) lead clinical program, bempeg plus Bristol-Myers' Opdivo, fails in registrational cancer studies. Nektar and Bristol-Myers decide to discontinue all bempeg plus Opdivo development programs.
J&J (JNJ) to Set the Tone for Pharma Sector's Q1 Earnings
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above the market. It remains to be seen if sales improved in the Medical Devices segment in the first quarter.
Seagen (SGEN) Gets Nod From EU for Bladder Cancer Drug, Padcev
by Zacks Equity Research
The European Commission approves Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.
Anthem (ANTM) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Anthem's (ANTM) first-quarter results are likely to benefit from the growing premiums and an uptick in Medicare and Medicaid membership, partly offset by higher expenses.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Merck (MRK) Stock Moves -1.2%: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $86.63, moving -1.2% from the previous trading session.
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
by Zacks Equity Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later this year.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
by Kinjel Shah
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
The Zacks Analyst Blog Highlights Merck, CVS Health, American Tower, QUALCOMM and Analog Devices
by Zacks Equity Research
Merck, CVS Health, American Tower, QUALCOMM and Analog Devices are part of top Analyst article.
Top Analyst Reports for Merck, CVS Health & American Tower
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co. Inc. (MRK), CVS Health Corporation (CVS), and American Tower Corporation (AMT).
Iovance (IOVA) to Seek FDA Nod for Melanoma Therapy in August
by Zacks Equity Research
Iovance (IOVA) expects to complete FDA filing for lifileucel in metastatic melanoma by August 2022. It also intends to start a phase III combo study with lifileucel in melanoma in late 2022.
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $83.72, moving +0.28% from the previous trading session.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.